Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Trading Down 6.7 %

Shares of NASDAQ:GLMD traded down $0.03 during trading on Friday, hitting $0.41. The company's stock had a trading volume of 215,780 shares, compared to its average volume of 112,427. The business has a 50 day moving average price of $0.53 and a two-hundred day moving average price of $1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.48. Galmed Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $3.39.

Galmed Pharmaceuticals (NASDAQ:GLMD - Get Rating) last posted its quarterly earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.09. On average, sell-side analysts forecast that Galmed Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Analyst Ratings Changes

GLMD has been the topic of several analyst reports. Canaccord Genuity Group lowered shares of Galmed Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, August 8th. Maxim Group lowered shares of Galmed Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, August 8th. Raymond James downgraded shares of Galmed Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 18th. Cantor Fitzgerald downgraded shares of Galmed Pharmaceuticals from an "overweight" rating to a "neutral" rating in a report on Thursday, August 4th. Finally, HC Wainwright downgraded shares of Galmed Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $5.00.